Effects of Initiating or Switching to a Six-Monthly Triptorelin Formulation on Prostate Cancer Patient–Healthcare Interactions and Hospital Resource Use: a Real-World, Retrospective, Non-Interventional Study-Reference-Cited by-同舟云学术

Effects of Initiating or Switching to a Six-Monthly Triptorelin Formulation on Prostate Cancer Patient–Healthcare Interactions and Hospital Resource Use: a Real-World, Retrospective, Non-Interventional Study

Published:2018-11-05 Issue:2 Volume:6 Page:173-187
ISSN:2366-1070
Container-title:Oncology and Therapy
language:en
Short-container-title:Oncol Ther

Author:

Cornford Philip,Jefferson Kieran,Cole Owen,Gilbody John

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

http://link.springer.com/content/pdf/10.1007/s40487-018-0087-1.pdf

Reference21 articles.

1. Cancer Research UK. Prostate cancer incidence statistics 2014. http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer/incidence . Accessed 20 March 2018.

2. Cancer Research UK. Prostate cancer mortality statistics 2014. https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer/mortality . Accessed 20 March 2018.

3. Cancer Research UK. Prostate cancer survival statistics. 2014. https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer . Accessed 20 March 2017.

4. Roehrborn CG, Black LK. The economic burden of prostate cancer. BJU Int. 2011;108:806–13.

5. Saunders R, Plun-Favreau J, Takizawa C, Valentine WJ. Clinical and economic burden of prostate cancer. Value Health. 2015;18:A449.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Increased use of 6-monthly gonadotropin-releasing hormone agonist therapy for prostate cancer: a capacity and cost-minimization analysis for England;Journal of Medical Economics;2023-02-07

2. Cost minimization and budget impact analysis of the use of a new 6-month form of triptorelin in the treatment of patients with prostate cancer in Ukraine;Farmatsevtychnyi zhurnal;2022-12-29

3. Experience of switching from a daily to a less frequent administration of injection treatments;PLOS ONE;2022-11-30